GSK 1004723
Alternative Names: GSK 1004723DLatest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Azepines; Phthalazines; Pyrrolidines
- Mechanism of Action Histamine H1 receptor antagonists; Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic rhinitis
Most Recent Events
- 23 Apr 2008 Phase-I clinical trials in Allergic rhinitis in Germany (Intranasal)